Protease Inhibitor Drugs for Candida Infections - Xinli Lin

Abstract

Funding Agency

Agency: National Institute of Health (NIH)
Institute: National Institute of Allergy and Infectious Diseases (NIAID)
Type: First Independent Research Support & Transition (FIRST) Awards (R29)
Project #: 5R29AI034273-04
Application #: 2069374
Study Section: AIDS and Related Research Study Section 4 (ARRD)

Project Start: 1993-04-01
Project End: 1998-03-31
Budget Start: 1996-04-01
Budget End: 1997-03-31
Support Year: 4
Fiscal Year: 1996
Total Cost
Indirect Cost

Institution

Name: Oklahoma Medical Research Foundation
Department
Type
DUNS #: 937727907

City: Oklahoma City
State: OK
Country: United States
Zip Code: 73104

Related projects


NIH 1997 R29 AI	Protease Inhibitor Drugs for Candida Infections Lin, Xinli / Oklahoma Medical Research Foundation
NIH 1996 R29 AI	Protease Inhibitor Drugs for Candida Infections Lin, Xinli / Oklahoma Medical Research Foundation
NIH 1995 R29 AI	Protease Inhibitor Drugs for Candida Infections Lin, Xinli / Oklahoma Medical Research Foundation
NIH 1994 R29 AI	Protease Inhibitor Drugs for Candida Infections Lin, Xinli / Oklahoma Medical Research Foundation
NIH 1993 R29 AI	Protease Inhibitor Drugs for Candida Infections Lin, Xinli / Oklahoma Medical Research Foundation

Publications

Koelsch, G; Tang, J; Loy, J A et al. (2000) Enzymic characteristics of secreted aspartic proteases of Candida albicans. Biochim Biophys Acta 1480:117-31

Lin, X; Tang, J; Koelsch, G et al. (1993) Recombinant canditropsin, an extracellular aspartic protease from yeast Candida tropicalis. Escherichia coli expression, purification, zymogen activation, and enzymic properties. J Biol Chem 268:20143-7

Comments

Be the first to comment on this grant